NeoGenomics Inc
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing se… Read more
NeoGenomics Inc (NEO) - Total Liabilities
Latest total liabilities as of September 2025: $536.49 Million USD
Based on the latest financial reports, NeoGenomics Inc (NEO) has total liabilities worth $536.49 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
NeoGenomics Inc - Total Liabilities Trend (2000–2024)
This chart illustrates how NeoGenomics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
NeoGenomics Inc Competitors by Total Liabilities
The table below lists competitors of NeoGenomics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Attendo AB (publ)
ST:ATT
|
Sweden | Skr19.60 Billion |
|
Navios Maritime Partners LP Unit
NYSE:NMM
|
USA | $2.69 Billion |
|
Lifestyle Communities Limited
PINK:LCOMF
|
USA | $685.75 Million |
|
Green Plains Renewable Energy Inc
NASDAQ:GPRE
|
USA | $806.42 Million |
|
Hangzhou Honghua Digital Technology Stock Company LTD
SHG:688789
|
China | CN¥1.09 Billion |
|
China Automotive Engineering Research Institute Co Ltd
SHG:601965
|
China | CN¥3.45 Billion |
|
Robertet S.A.
LSE:0NZN
|
UK | €450.06 Million |
|
Revolve Group LLC
NYSE:RVLV
|
USA | $261.05 Million |
Liability Composition Analysis (2000–2024)
This chart breaks down NeoGenomics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.91 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.64 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NeoGenomics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NeoGenomics Inc (2000–2024)
The table below shows the annual total liabilities of NeoGenomics Inc from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $735.70 Million | -0.54% |
| 2023-12-31 | $739.69 Million | -0.31% |
| 2022-12-31 | $742.01 Million | -2.56% |
| 2021-12-31 | $761.50 Million | +158.98% |
| 2020-12-31 | $294.04 Million | +45.49% |
| 2019-12-31 | $202.10 Million | +9.50% |
| 2018-12-31 | $184.57 Million | +33.94% |
| 2017-12-31 | $137.81 Million | -8.45% |
| 2016-12-31 | $150.52 Million | +15.93% |
| 2015-12-31 | $129.84 Million | +527.23% |
| 2014-12-31 | $20.70 Million | +13.71% |
| 2013-12-31 | $18.20 Million | -12.71% |
| 2012-12-31 | $20.86 Million | +48.41% |
| 2011-12-31 | $14.05 Million | +33.62% |
| 2010-12-31 | $10.52 Million | +44.02% |
| 2009-12-31 | $7.30 Million | +26.02% |
| 2008-12-31 | $5.79 Million | +38.00% |
| 2007-12-31 | $4.20 Million | +36.44% |
| 2006-12-31 | $3.08 Million | +48.31% |
| 2005-12-31 | $2.08 Million | +103.70% |
| 2004-12-31 | $1.02 Million | +16.44% |
| 2003-12-31 | $874.84K | +106.09% |
| 2002-12-31 | $424.49K | +127.96% |
| 2001-12-31 | $186.22K | +48.94% |
| 2000-12-31 | $125.03K | -- |